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Macrophages control the resolution of inflammation
through the transition from a proinflammatory (M1)
to an anti-inflammatory (M2) phenotype. Here, we
present evidence for a role of AMPKa1, a master
regulator of energy homeostasis, in macrophage
skewing that occurs during skeletal muscle regene-
ration. Muscle regeneration was impaired in
AMPKa1/ mice. In vivo loss-of-function (LysM-
Cre;AMPKa1fl/fl mouse) and rescue (bone marrow
transplantation) experiments showed that macro-
phagic AMPKa1 was required for muscle regene-
ration. Cell-based experiments revealed that
AMPKa1/ macrophages did not fully acquire the
phenotype or the functions of M2 cells. In vivo,
AMPKa1/ leukocytes did not acquire the expres-
sion of M2 markers during muscle regeneration.
Skewing from M1 toward M2 phenotype upon
phagocytosis of necrotic and apoptotic cells was
impaired in AMPKa1/ macrophages and when
AMPK activation was prevented by the inhibition of
its upstream activator, CaMKKb. In conclusion,
AMPKa1 is crucial for phagocytosis-induced macro-
phage skewing from a pro- to anti-inflammatory
phenotype at the time of resolution of inflammation.
INTRODUCTION
The inflammatory response is a spatially and temporally coordi-
nated process. The proinflammatory mechanisms initiated and
amplified at the onset of the inflammatory response must be
controlled in order to avoid excessive tissue damage. Macro-
phages play important roles in the resolution of inflammationCel(Mosser and Edwards, 2008; Lawrence and Fong, 2010).
Although the first steps of the inflammatory response are associ-
ated with proinflammatory (M1) macrophages, which secrete
proinflammatory compounds, the resolution of inflammation is
associated with M2 macrophages, which exhibit an anti-inflam-
matory phenotype (Mosser and Edwards, 2008). Studies both
in vivo and in vitro have demonstrated that macrophages can
undergo dynamic transitions between the M1 and M2 states of
activation, which is called polarization skewing (Mosser and
Edwards, 2008; Lawrence and Fong, 2010). Recently, different
regulatory pathways have been associated with either the M1
or M2 activation states. They involve a variety of molecular
machineries at the genomic, transcriptomic, and posttranscrip-
tomic levels (reviewed in Lawrence and Natoli, 2011). Despite
these recent advances, the signaling pathways involved in regu-
lating the skewing of the macrophage from the M1 to M2 pheno-
type are poorly understood.
AMP-activated protein kinase (AMPK), which is composed of
a catalytic (a) and two regulatory (b and g) subunits, senses the
cellular energy levels as forms of ADP:ATP and AMP:ATP ratios.
An extensive amount of literature has been published on the
roles of AMPK in the regulation of a multitude of metabolic pro-
cesses that maintain cellular energy homeostasis (reviewed in
Hardie, 2011). Besides these functions, it has recently been
reported that enhanced AMPK activation is associated with a
decrease of the inflammatory response. Thus far, most of the
published work was completed in the context of bacterial infec-
tion; i.e., upon bacterial lipopolysaccharide (LPS) stimulation.
Both genetic and pharmacological blocking of AMPK resulted
in an enhanced proinflammatory response, whereas AMPK acti-
vation decreases the secretion of proinflammatory factors by
macrophages in vitro (Jeong et al., 2009; Peairs et al., 2009;
Sag et al., 2008; Zhao et al., 2008; Giri et al., 2004). In vivo, the
administration of 5-amino-1-b-D-ribofuranosyl-imidazole-4-car-
boxamide (AICAR), a pharmacological AMPK activator, attenu-
ates LPS-induced acute lung injury (Zhao et al., 2008), whereas
its inhibition leads to the opposite effect (Xing et al., 2013). Thesel Metabolism 18, 251–264, August 6, 2013 ª2013 Elsevier Inc. 251
Figure 1. Effects of AMPKa1 Loss on Skeletal Muscle Regeneration
WT (white bars) and AMPKa1/ (black bars) TA muscle was injured with CTX and analyzed at several days (D in the x axes) postinjury.
(A) AMPKa1 activity measured in whole WT muscle lysate.
(B) The percentage of GFP+ cells; i.e., macrophages from WT regenerating CX3CR1GFP/+ mouse muscle.
(legend continued on next page)
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proinflammatory status of macrophages. However, its role in
the acquisition of an anti-inflammatory or M2 status has not
been investigated, nor has its role in the regulation of the inflam-
matory profile of macrophages during the resolution of
inflammation.
In the present study, we address the role of AMPKa1 in mac-
rophages, the sole AMPKa catalytic unit isoform expressed in
these cells (Sag et al., 2008), during skeletal muscle regenera-
tion. After an injury, skeletal muscle regenerates ad integrum
because of the properties of the satellite cells, the main adult
muscle stem cells. It has been shown that macrophages accom-
pany this process by sequentially adopting at least two main
inflammatory profiles (Arnold et al., 2007; Saclier et al., 2013).
Soon after injury, muscle-associated macrophages exhibit a
proinflammatory profile and stimulatemyogenic precursor prolif-
eration. From 24 hr to 72 hr later, these macrophages skew into
anti-inflammatory or M2 macrophages that stimulate the termi-
nal differentiation of myogenic precursor cells, their fusion into
myotubes, and the growth of the new regenerating myofibers
(Arnold et al., 2007). Thus, postinjury skeletal muscle regenera-
tion provides an excellent paradigm for studying events related
to the resolution of inflammation. For the present study, we
used various genetic mouse models and culture setups, both
in vivo and in vitro, to explore the role of macrophagic AMPKa1
at the time of resolution of inflammation.
RESULTS
AMPKa1 Is Required for Skeletal Muscle Regeneration
Skeletal muscle regeneration after intramuscular (i.m.) injection
of cardiotoxin (CTX) provides a useful model for sterile inflamma-
tion. It provides a homogenous damage in the whole muscle
(Figure S1A available online) and triggers the infiltration of a great
number of monocytes or macrophages in the regenerating mus-
cle until the end of repair (Figure S1B) (Arnold et al., 2007; Sun
et al., 2009). In the CX3CR1GFP/+ mouse, monocyte or macro-
phage subsets can be traced by the GFP label along with the
LY6C/G (Gr1) label (Geissmann et al., 2003; Arnold et al.,
2007). The kinetics of AMPKa1 activity during skeletal muscle
regeneration (Figure 1A) paralleled the curve of macrophage
appearance into regenerating muscle (Figure 1B), a pronounced
increase (+107%, p < 0.001) occurring from the time of injury to
days 2–4, and a decline occurring after day 4. Evaluation of
AMPKa1 activity in isolated macrophages confirmed the in-
crease in AMPKa1 activity at day 4 (+135%) (Figure 1C).
AMPKa2 activity was very low in comparison to normal muscle
in wild-type (WT) and AMPKa1/ mice (Figure 1D). Given that(C) AMPKa1 activity measured in F4/80+ macrophages isolated from WT regene
(D) AMPKa2 activity measured in whole muscle lysate.
(E) Hematoxylin-eosin (HE) staining of regenerating muscle. Crosses (x) indica
indicate basophilic myofibers.
(F) Quantification of regeneration assessed by the percentage of necrotic, ph
myofibers expressed as a percentage of the total number or myofibers.
(G) Distribution of myofiber CSAs at day 14 postinjury (left) and mean CSA (right
(H) Specific mass of TA muscle. Results are means ± SEM from at least five anim
*p < 0.05, **p < 0.01, and ***p < 0.001 for AMPKa1/ versus WT muscle. #p < 0
represents 50 mm.
See also Figure S1.
CelAMPKa1 is the sole catalytic subunit expressed in macrophages
(Sag et al., 2008), we explored its role during muscle regenera-
tion. The postinjury regeneration process induced by CTX in
the tibialis anterior (TA) muscle follows a sequence of well-char-
acterized events (Figure 1E). The first phase (1–7 days) includes
the necrosis of myofibers, invasion of the injured area by inflam-
matory cells (neutrophils rapidly followed bymacrophages), pro-
liferation of myogenic precursor cells (MPCs), phagocytosis of
damaged myofibers by macrophages, and differentiation of
MPCs. A second phase (7–14 or 7–21 days) includes the contin-
uation of MPC differentiation, formation, and then the growth of
newmyofibers, which are characterized by the central location of
their nuclei.
Histological analysis shows that skeletal muscle repair was
delayed in AMPKa1/ animals from day 2 postinjury (Figure 1E).
First, in AMPKa1/ mice, there was a significantly higher num-
ber of necrotic myofibers in comparison to WT mice (+38%
and +843%, p < 0.01 and 0.05 at day 2 and 4, respectively) (Fig-
ures 1E and 1F). A delay in the disappearance of damaged phag-
ocyted myofibers was also observed in AMPKa1/ mice
(+103% at day 4; p < 0.01) (Figures 1E and 1F). Consequently,
the number of newly formed myofibers (appearing basophilic)
was delayed (56% and 10%, p < 0.01 and 0.05 at days 4
and 7, respectively) (Figures 1E and 1F). The cross-section
area (CSA) of the regenerating myofibers in AMPKa1/ mice
was smaller in comparison to WT mice 14 days postinjury
(55% decrease, p < 0.001) (Figures 1E and 1G). The distribution
of the myofiber CSA of AMPKa1/ mice showed a shift to the
left, exhibiting more small myofibers and fewer large myofibers
(Figures 1E and 1G). A decrease of 37% inmyofiber CSAwas still
observed 2 months postinjury (day 56) in AMPKa1/ muscle
(p < 0.05), indicating that muscle regeneration was impaired (Fig-
ures 1E and 1G). Due to a decrease in myofiber size, a decrease
inmusclemasswas observed in AMPKa1/ animals in compar-
ison to WT animals (Figure 1H). Several parameters related to
myogenesis showed no difference between the two strains
(data not shown). In WT and AMPKa1/ muscles at days
0 and 21, similar numbers were found of (1) myonuclei per fiber,
suggesting that the fusion process was not altered by AMPKa1
deficiency, (2) Pax7+ satellite cells, suggesting no strong alter-
ation in muscle cell homeostasis, and (3) myofibers expressing
succinate dehydrogenase (a marker of oxidative metabolism)
in WT and AMPKa1/ muscles at days 0 and 14, suggesting
no alteration of myofiber metabolism during regeneration. Force
measurement was not performed because previous studies
showed that functional recovery after CTX injury is not achieved
after 3–6 months in normal skeletal muscle despite normalized
histology (Vignaud et al., 2005, 2006). Although one cannotrating mouse muscle. Each symbol represents one independent experiment.
te necrotic myofibers, asterisks (*) show phagocyted myofibers, and arrows
agocyted, regenerating (basophilic), and regenerating (centrally nucleated)
).
als.
.05, ##p < 0.01, and ###p < 0.001 versus day 0 or day 2 muscle. The scale bar
l Metabolism 18, 251–264, August 6, 2013 ª2013 Elsevier Inc. 253
Figure 2. Effects of Loss-of-Function and
Rescue of Macrophagic AMPKa1 on Skel-
etal Muscle Regeneration
(A–D) In loss-of-function experiments, LysM-
a1/ and AMPKa1fl/fl (as a control) TA muscles
were injured with CTX and analyzed 7 (D7) and 14
(D14) days postinjury.
(A) HE staining of regenerating muscle.
(B) Quantification of necrotic and phagocyted
myofibers expressed as a percentage of the total
number of myofibers.
(C and D) Distribution (C) and mean (D) of myofiber
CSAs.
(E–H) In rescue experiments, BM transplantation
of AMPKa1/ mice was performed with WT BM
(BMWT- > KO) or with AMPKa1/ BM (BMKO- >
KO) as a control. After 10 weeks, TA muscle was
injured with CTX and analyzed 14 days later.
(E) The presence of GFP+ (green) macrophages
from donor (CX3CR1GFP/+) mice in recipient re-
generating muscle. Laminin staining is shown in
red, and nuclei are shown in blue.
(F) HE staining of regenerating muscle.
(G and H) Distribution (G) andmean (H) of myofiber
CSAs. Results are means ± SEM from at least five
animals.
*p < 0.05, **p < 0.01, and ***p < 0.001 versus WT
muscle. The scale bar in (A) and (F) represents
50 mm, and the scale bar in (E) represents 100 mm.
See also Figure S2.
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AMPKa1 Regulates Macrophage Skewingexclude the contribution of AMPKa1 activity in several cell types
(including myofibers) in AMPKa1/ total knockout (KO) muscle,
particularly for the late time points, the alteration of inflammation
has previously been shown to directly impact muscle regenera-
tion and myofiber size (Arnold et al., 2007; Perdiguero et al.,
2011; Martinez et al., 2010).
Macrophagic AMPKa1 Is Required for Proper Skeletal
Muscle Regeneration
Loss-of-function experiments were performed by crossing
floxed AMPKa1 mice with the myeloid-specific LysM-CRE strain
(Clausen et al., 1999). In the resulting LysM-CRE;AMPKa1fl/fl
(herein named LysM-a1/) mice, AMPKa1 protein was unde-
tectable in peritoneal macrophages (Figure S2A). The percent-
age of deletion of AMPKa1 gene at the genomic level was null
in the tail (data not shown) and increased to 73% in bonemarrow
(BM)-derived macrophages (BMDM) (in comparison to 49% in254 Cell Metabolism 18, 251–264, August 6, 2013 ª2013 Elsevier Inc.total BM) and to 84% in macrophages
isolated from regenerating muscle (in
comparison to 56% in muscle-derived
CD45+ cells), thus indicating the speci-
ficity of the deletion (Figure S2B). AMPK
levels were similar in resting muscle
from AMPKa1fl/fl and LysM-a1/ mice,
indicating no leakage of LysM-Cre in
myofibers (Figure S2C).
Skeletal muscle regeneration in
LysM-a1/ mice showed a significant
delay (Figures 2A–2D). At day 7, an in-
crease of necrotic and phagocytic myo-fibers was observed (+300%, p < 0.05) (Figures 2A and 2B). At
day 14, the distribution of myofiber CSA showed a reduction in
the size of regenerating myofibers in LysM-a1/ in comparison
to WT muscle (Figure 2C). Accordingly, mean CSA was
decreased by 17% in comparison to WT mice (p < 0.01) (Figures
2A and 2D).
Rescue experiments included the transplantation of
AMPKa1+/+;CX3CR1GFP/+ and AMPKa1/;CX3CR1GFP/+
BM into total AMPKa1/ recipients, hereafter indicated as
BMWT- > KO and BMKO- > KO, respectively. Recipient muscles
were injured with CTX 10 weeks after BM transplantation and
analyzed 14 days later. Figure 2E shows infiltrating GFP+
donor-derived cells in the regenerating skeletal muscle of trans-
planted animals, indicating the efficiency of BM transplantation.
Skeletal muscle regenerated more efficiently in the BMWT- > KO
in comparison to BMKO- > KO muscle (Figure 2F), as illustrated
by a significant shift to the right of the distribution of the myofiber
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AMPKa1 Regulates Macrophage SkewingCSA (Figure 2G) and an increased mean CSA of regenerating
myofibers (+49%, p < 0.001) (Figure 2H). These results show
that AMPKa1 is required for the regulation of macrophage func-
tions during muscle regeneration.
AMPKa1–/– Macrophages Do Not Acquire M2
Phenotypes In Vitro
BMDM from WT and AMPKa1/ animals were polarized with
cytokines in order to trigger various inflammatory profiles.
IFNg, IL4, and IL10 treatments elicited proinflammatory (M1),
alternative activation (M2a), and anti-inflammatory (M2c) states,
respectively (Martinez et al., 2008). We analyzed 12 genes by
quantitative RT-PCR (qRT-PCR) (Figure S3A). Results show
that M1 polarization was achieved in these in vitro conditions;
i.e., messenger RNAs (mRNAs) of the M1 markers (Tnf, il1b,
ptgs2, and Nos2) were strongly expressed in M1 WT macro-
phages. High variations were observed among primary cultures
for the expression of the M2 marker mRNAs (Tgfb1, il10, il4ra,
Vcam1, Chia, Arg1, Retnla, and Chi3l3), although a strong ten-
dency toward an increase of some of these markers was
observed in WT M2 versus M1 macrophages, especially for
M2a markers (Chia, Arg1, Retnla, and Chi3l3) (Figure S3A). As
a whole, no significant difference of marker mRNA expression
was observed between WT and AMPKa1/ macrophages (Fig-
ure S3A). Given that the regulation of inflammatory effectors is
finely regulated at the posttranscriptional level (Lawrence and
Natoli, 2011), the expression of seven markers of macrophage
polarization was analyzed at the individual cell level by immuno-
fluorescence. Figures 3A and S3B confirmed that the polariza-
tion was achieved in WT macrophages; i.e., a higher number of
M1 macrophages expressed proinflammatory markers (CCL3
and iNOS) in comparison to M2 macrophages. M2a and M2c
macrophages more highly expressed M2 markers (TGFb1,
CD206, and CD163) (Figure 3A). The expression of COX-2 and
Arginase 1 was not significantly changed (Figure 3A).
AMPKa1/M1macrophages showed no difference in compar-
ison toWTmacrophages, except in the case of iNOS expression,
which was increased (+33%, p < 0.05) (Figure 3A). Conversely,
M2macrophages (both M2a andM2c) derived from AMPKa1/
mice exhibited altered activation profiles. A higher number of
M1-marker-expressing cells was observed in AMPKa1/
versus WT M2 macrophages (+50 and +70% for CCL3 and
iNOS, respectively, for M2c cells, p < 0.05; +63% for iNOS for
M2a cells, p = 0.055). Moreover, the number of macrophages
expressing M2 markers was decreased in both M2c (33%
[p < 0.001], 21% [p < 0.05], and 50% for CD206, CD163,
and TGFb1, respectively) and M2a (41% [p < 0.001], 18%
[p < 0.01], and 33% [p < 0.01] for CD206, CD163, and TGFb,
respectively) macrophages (Figure 3A). Flow cytometry analysis
showed that mean fluorescent intensity of the M2 markers
CD206 and Mgl1 (CD301) was increased in WT M2a macro-
phages (+671% and +914% in comparison to M1 cells, p <
0.05), whereas a much weaker increase was observed in
AMPKa1/ macrophages (+441 and +449%, p < 0.05) (Fig-
ure 3B). High oxygen consumption rate (OCR) has been shown
to be associated with the M2 phenotype (Haschemi et al.,
2012). As expected, M2a macrophages showed an increased
basal and maximal OCR in comparison to M1 and M2c macro-
phages (+130 and +143% for basal and maximal OCR of M2aCelversus M1 macrophages, p < 0.05). This increase was not
observed in AMPKa1/ cells (Figure 3C). Moreover, the activa-
tion of AMPK with AICAR induced a decrease of M1 (iNOS) and
an increase of M2 (CD206) marker expression in WT macro-
phages, and these changes were not observed in AMPKa1/
macrophages (Figure 3D). Altogether, these results show that
AMPKa1/ macrophages were not able to fully adopt an M2
phenotype upon cytokine stimulation and kept a proinflamma-
tory profile.
Previously, we showed that M1 macrophages stimulate MPC
proliferation, whereas M2macrophages promote their differenti-
ation. This is of particular interest for myogenic cell fate during
muscle regeneration, where a sequential presence of M1 then
M2 macrophages accompanies the regeneration process
(Arnold et al., 2007; Saclier et al., 2013). Coculture experiments
were performed in which macrophage-conditioned medium
was added to MPCs. As expected, WT M1 macrophages stimu-
lated MPC proliferation (+45%, p < 0.01) (Figure 4A), whereas
WT M2a and M2c macrophages promoted MPC fusion into
myotubes (+63% and +57%, p < 0.05 and p < 0.01, respectively)
(Figure 4B). AMPKa1/ M2 macrophages stimulated the prolif-
eration of MPCs (Figure 4A), and they were not able to sustain
their fusion (Figure 4B). Moreover, conditioned medium from
AICAR-treated WT macrophages stimulated MPC fusion, which
was indicative of an M2 phenotype, whereas this increase was
not observed in AMPKa1/ macrophages (Figure 4C). These
results confirmed that AMPKa1/ macrophages failed to ac-
quire an M2 phenotype.
AMPKa1–/– Macrophages Do Not Acquire M2 Phenotype
In Vivo
Next, the capability of AMPKa1/ macrophages to switch their
phenotype was assessed in vivo during skeletal muscle regener-
ation. Flow cytometry analysis showed that themain CD45+ pop-
ulation consisted of macrophages from the first stages of muscle
regeneration (72% at day 2 and 75% at day 4) until the almost
complete disappearance of CD45+ cells (35% at day 8) (Fig-
ure 5A). CD45+ cells were extracted from regenerating WT and
AMPKa1/ muscle at different time points and analyzed by
immunolabeling. In WT leukocytes, the number of cells express-
ing M1 markers (CCL3 and iNOS) decreased with time (Fig-
ure 5B). Conversely, the number of cells positive for M2 markers
(TGFb1, CD206, and CD163) increased during muscle regenera-
tion, the exception being Arginase 1 (Figure 5B). In AMPKa1/
leukocytes, this kinetic was altered. The number of leukocytes
expressing M1 markers was maintained, whereas the number
of leukocytes expressing M2 markers did not significantly
increase during muscle regeneration (Figure 5B). These results
show that intramuscular AMPKa1/ macrophages did not
acquire an M2 phenotype at the time of resolution of
inflammation.
AMPKa1+/+; CX3CR1GFP/+ and AMPKa1/; CX3CR1GFP/+
mice were used to track neutrophils (Ly6C/G+ CX3CR1/GFP),
M1 macrophages (Ly6C/G+ CX3CR1/GFPlo), and M2 macro-
phages (Ly6C/Gneg CX3CR1/GFPhi) during skeletal muscle
repair. This model has proven to be useful for tracking the early
events of monocyte or macrophage subset infiltration into tis-
sues and following their subsequent fate (Ginhoux et al., 2006;
Zigmond et al., 2012; Rivollier et al., 2012). M2 macrophagesl Metabolism 18, 251–264, August 6, 2013 ª2013 Elsevier Inc. 255
Figure 3. Effects of AMPKa1 Loss on Macrophage Inflammatory Phenotype after In Vitro Polarization
WT and AMPKa1/ BMDM were activated into M1, M2c, and M2a macrophages with IFNg, IL10, and IL4 treatment, respectively, for 3 days.
(A) Cells were tested for the expression of a series of M1 and M2 markers by immunofluorescence. Results are expressed as a percentage of positive cells.
(B) M2 markers (CD206 and Mgl1/CD301) were analyzed by flow cytometry. Left, the evaluation of specific mean fluorescence intensity. Right, representative
histograms of M2a macrophages.
(C) Measurement of OCR in basal conditions (Basal) or after stimulation of WT and AMPKa1/ (KO) macrophages with carbonylcyanide m-chlorophenylhy-
drazone (Max).
(D) Expression of iNOS and CD206 after the stimulation of macrophages with AICAR. Results are means ± SEM for at least three independent experiments.
*p < 0.05, **p < 0.01, and ***p < 0.001 for AMPKa1/ versus WT macrophages. #p < 0.05 and ##p < 0.01 versus M1 macrophages. £p < 0.05 versus nontreated
cells (NT).
See also Figure S3.
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Figure 4. Effects of AMPKa1 Loss on Macro-
phage Functions after In Vitro Polarization
WT and AMPKa1/ BMDM were polarized as in
Figures 3A and 3B or treated with AICAR (C), and
conditioned medium was added to MPCs.
(A) MPC proliferation wasmeasured as a percentage
of ki67+ cells (red, ki67; blue, Hoechst).
(B and C) The MPC fusion index was calculated after
desmin labeling (red, desmin; blue, Hoechst). Re-
sults are means ± SEM of at least three independent
experiments.
*p < 0.05 and **p < 0.01 AMPKa1/ versus WT
muscle. #p < 0.05, ##p < 0.01, and ###p < 0.001
versus M1 macrophages. $p < 0.05 and $$p < 0.01
versus None. £p < 0.05 and ££p < 0.01 versus NT
cells. The scale bar represents 20 mm.
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injury (Figure 6A). The homeostasis of circulating monocyte sub-
sets in AMPKa1/;CX3CR1GFP/+ mice was not altered (data not
shown). Moreover, the number of infiltrating neutrophils and
macrophages was similar in WT and AMPKa1/ muscle 1 day
postinjury (Figure 6B), excluding a defect of leukodiapedesis
in AMPKa1/. At the time of resolution of inflammation,
CX3CR1-GFPloLy6C/G+ cells convert into CX3CR1-GFPhi
Ly6C/G— cells (Arnold et al., 2007). The distribution of the two
macrophage subsets was altered in AMPKa1/ regenerating
muscle, and a delay occurred in the appearance of the M2 sub-
set (Figure 6C). At day 1, a small number of M2 cells were pre-
sent. In AMPKa1/ muscle, M2 cells were already less
numerous than they were in WT muscle (38.7%, p < 0.05) (Fig-Cell Metabolism 18, 251–ure 6C). From day 2, the switch from M1 to
M2 occurred inWTmuscle. M2 cell number
was still decreased in AMPKa1/ in com-
parison to WT muscle (14.0% at day 2,
p < 0.05, 16.3% at day 3, p = 0.08) (Fig-
ure 6C). Accordingly, the M2:M1 ratio was
about 50% lower in AMPKa1/ muscle
for all time points (p < 0.05) (Figure 6C).
Similar results were obtained in LysM-
a1/ mice, where the M2 subset was
reduced in comparison to the control
(11% at day 2, p < 0.05) (Figure 6D). Anal-
ysis was not carried on at later time points
given that, from day 4, the inflammatory
phenotype of GFP+ populations changes
(Perdiguero et al., 2011). These results
show that, in the absence of AMPKa1, a
part of M1 macrophages failed to switch
to M2 at the time of resolution of
inflammation.
AMPKa1–/– Macrophages Show a
Defect in Phagocytosis
Phagocytosis of necrotic and apoptotic
MPCs by macrophages decreases their
TNFa secretion and increases their TGFb
secretion, indicating that phagocytosis of
muscle debris participates to macrophageskewing (Arnold et al., 2007). Differentially activated macro-
phages exhibited a similar phagocytic activity of necrotic and
apoptotic MPCs, which was decreased in AMPKa1/ macro-
phages (42% for M1 and 35% for M2a macrophages, p < 0.05)
(Figure 7A). As expected, in WT M1 macrophages, the expres-
sion of M1 markers was decreased upon phagocytosis (by
36% and 34% for iNOS and CCL3, p < 0.001 and 0.01, respec-
tively), whereas that of M2markers was increased (by 45%, 46%
and 29% for TGFb1, CD163, and CD206, p < 0.05, 0.01, and
0.01, respectively) (Figure 7B). AMPKa1/ macrophages did
not present this phenotypic transition upon phagocytosis, given
that the expression of neither of these markers was altered,
except that of CD206, which was even decreased (Figure 7B).
These results show that phagocytosis was impaired in264, August 6, 2013 ª2013 Elsevier Inc. 257
Figure 5. Effects of AMPKa1 Loss on In Vivo Macrophage Inflammatory Phenotype during Muscle Regeneration
(A) The number of CD45+ cell populations was evaluated by flow cytometry analysis during muscle regeneration and expressed per mg of muscle.
(B) WT (white circles) and AMPKa1/ (black circles) TA muscle was injured with CTX, and CD45+ cells were extracted at several days (D in the x axes) postinjury,
cytospined, and tested for the expression of M1 and M2 markers by immunofluorescence. Results are expressed as a percentage of positive cells and are
means ± SEM of at least three independent experiments.
*p < 0.05 for AMPKa1/ versus WT muscle. #p < 0.05 and ##p < 0.01 versus day 2 muscle. The scale bar represents 20 mm.
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Figure 6. Effects of AMPKa1 Loss on the
Switch of Macrophage Inflammatory Pheno-
type during Muscle Regeneration
TA muscle was injured with CTX and analyzed for
cell population repartition by flow cytometry after
the extraction of CD45+ cells.
(A) In WT (AMPKa1+/+;CX3CR1GFP/+) and
AMPKa1/ (AMPKa1/;CX3CR1GFP/+) muscle,
three populations can be separated: CX3CR1/
GFP Ly6C/Ghi (neutrophils, N), CX3CR1/GFPlo
Ly6C/Ghi (M1), and CX3CR1/GFPhi Ly6C/G (M2)
macrophages (example of a dot plot at day 2
postinjury). Below, histograms of CD206 im-
munolabeling show a higher expression by Ly6Clo
macrophages, confirming their M2 phenotype.
(B) The number of macrophages (CXRCR1/GFP+
cells) and neutrophils was evaluated per mg of
muscle 1 day postinjury.
(C) M2 macrophage number was expressed as a
percentage of total macrophages at days 1, 2, and 3
postinjury. TheM2:M1 ratio isgiven in the rightpanel.
(D) Similar analyses of macrophage subsets were
performed in LysM-a1/ (versus AMPK1fl/fl) mus-
cle, inwhichM2macrophagesubsetwasexpressed
as a percentage of total macrophages (gated as F4/
80+ cells) 2 days postinjury. Results are means ±
SEM of at least three independent experiments.
*p < 0.05 for AMPKa1/ versus WT. The scale bar
represents 50 mm.
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associated with phagocytosis could not properly operate in
these cells.
AMPK activation can be triggered by upstream LKB1 and
CaMKKb kinases (Hawley et al., 2005; Woods et al., 2005). In
mice deficient for LKB1 in the myeloid lineage (LysM-LKB1/)
(Figures S2D and S2E), no phenotypic difference was observed
in comparison to the control. Muscle regeneration followed
similar kinetics in LysM-LKB1/ and control (LKB1fl/fl) mice (Fig-
ure S4A). The ratio between M1 and M2 macrophages at day 2
postinjury was similar in both genotypes (Figure S4B). These re-
sults suggest that LKB1 plays no or little role in AMPK activation
in macrophages during muscle regeneration. To explore the role
of CaMKKb, we took advantage of the selective pharmacological
CaMKK inhibitor STO-609 (Tokumitsu et al., 2002; Hawley et al.,
2005; Woods et al., 2005), which leads to the CaMKKb-activated
inhibition of AMPK activation (Hawley et al., 2010). We observed
that WT M2 macrophages treated with STO-609 did not
decrease the expression of the M1 marker iNOS and increasedCell Metabolism 18, 251–2the expression of the M2 marker CD206
in a manner that was much weaker than
that of untreated M2 macrophages (41
and 56% increase in STO-609-treated
M2a and M2c versus 68 and 70% in
untreated macrophages) (Figure 7C).
Moreover, phagocyting M1 macrophages
treated with STO-609 did not decrease
iNOS expression or increase CD206
expression, which was in contrast to
untreated macrophages (Figure 7D).
Finally, we analyzed the phosphorylationof AMPK with a specific antibody in situ during skeletal muscle
regeneration (Figure 7E). At day 2 postinjury, macrophages
(F4/80+ cells) associated with phagocytosis of myofibers
expressed p-AMPK, whereas interstitial macrophages did not
(Figure 7E). At day 7, almost all the myofibers were in a regener-
ating state, and the remaining macrophages, which were not
labeled for phospho-AMPK (p-AMPK), were in the interstitium,
(Figure 7E). However, rare isolated areas of single myofiber
necrosis may still be observed. In these areas, macrophages
carrying out phagocytosis were positive for p-AMPK. No labeling
was observed in AMPKa1/ muscle (Figure 7E). Altogether,
these results suggest a link between the phagocytosis of
necrotic and apoptotic debris, CaMKKb, and AMPK activation
in the skewing of macrophages toward an M2 phenotype.
DISCUSSION
The results presented in this study show that the absence of
AMPKa1 in macrophages prevented their phenotypic transition64, August 6, 2013 ª2013 Elsevier Inc. 259
(legend on next page)
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macrophages exhibited a defect in the acquisition of theM2phe-
notypes, both in vivo and in vitro. Consequently, macrophage
functions were altered, and muscle regeneration was impaired.
AMPKa1 deficiency in macrophages prevented the acquisi-
tion of an M2 phenotype in vitro, as assessed by the lower
expression of M2 markers and the higher expression of M1
markers upon IL4 and IL10 stimulation or AICAR treatment.
Analyzing a battery of markers provides useful information on
the in vitro activation of BMDM. First, the analysis ofmacrophage
inflammatory state by qRT-PCR was not accurate in regard to
the M2c phenotype. Only the M1 and, to some extent, M2a state
could be defined by qRT-PCR analysis. Second, the expression
of markers at the mRNA level in the whole population and at the
protein level in individual cells showed high discrepancies. These
differences were most likely due to the unexpected heterogene-
ity of the macrophage populations. Our results show that,
although stimulated by a unique cytokine, the macrophage pop-
ulations remained heterogeneous; i.e., all the tested markers
were expressed by M1, M2a, and M2c macrophages by at least
15% or 30% of the cells. Finally, COX-2 (ptgs2) and Arginase 1
(Arg1), which are considered ‘‘canonical’’ markers in defining
M1 and M2 activation, respectively, were not useful in discrimi-
natingmousemacrophage activation states in our setting. These
results indicate that a series of markers should be examined at
the cellular level in order to properly assess the macrophage in-
flammatory state.
Several functions were found altered in AMPKa1/ macro-
phages. A metabolic switch is associated with the distinct
functions of M1 and M2 macrophages (Vats et al., 2006; Rodrı´-
guez-Prados et al., 2010; Haschemi et al., 2012). M2a
AMPKa1/macrophages did not display the increase of oxida-
tive phosphorylation observed in WT M2a macrophages, con-
firming that the induction of mitochondrial fatty acid oxidation
is related to the M2 phenotype. Similarly, AMPKb1 deficiency
in macrophages results in reduced rates of fatty acid oxidation
and altered M1:M2 polarization (Galic et al., 2011). Moreover,
in vitro functional analysis showed that AMPKa1/ macro-
phages prone to M2 polarization were not able to sustain myo-
genesis. They stimulated MPC proliferation and inhibited MPC
fusion just as WT M1 macrophages did, indicating that they did
not acquire an M2 phenotype. During muscle regeneration, M1
macrophages first stimulate MPC proliferation, then M2 macro-Figure 7. AMPKa1, CaMKKb, Phagocytosis, and Macrophage Polariza
(A) WT and AMPKa1/ BMDM were polarized as in Figure 3, incubated with fluo
against F4/80. Phagocytosis is expressed as a percentage of double-positive cells
of dot plots gated on F4/80+ cells, and the right panel shows an example of apo
(B) M1 macrophages were either incubated (gray bars) or not incubated (white
evaluated by immunofluorescence.
(C) WT BMDM were polarized in the absence or presence of STO-609, an inhibi
fluorescence.
(D) WT M1 macrophages were incubated with apoptotic MPCs in the absence
immunofluorescence.
(E) RegeneratingWT (three examples on the left) and AMPKa1/ (one example on
(F4/80, red) and phospho-AMPK (green). White arrows indicate phagocytosis-a
macrophages negative for p-AMPK. Yellow arrows indicate phagocytosis-associa
p-AMPK. Results are means ± SEM of at least three independent experiments.
*p < 0.05 and **p < 0.01 for AMPKa1/ versus WT macrophages. #p < 0.05, ##p
STO-609 versus DMSO-treated cells. £p < 0.05, ££p < 0.01, and £££p < 0.001 ver
See also Figure S4.
Celphages stimulate terminal myogenesis (Arnold et al., 2007; Sac-
lier et al., 2013). The defect of M2 AMPKa1/ macrophages in
sustaining in vitro myogenesis explains the impairment of regen-
eration observed in AMPKa1/ and LysM-a1/ muscles.
Inversely, activating AMPK with AICAR in macrophages pro-
moted myogenesis through their skewing into M2 cells. There-
fore, aside from its direct effects on myofiber energy metabolism
(Narkar et al., 2011), AMPK may indirectly act on myogenesis
through the properties of macrophages during muscle
regeneration.
In vivo investigations confirmed the in vitro results. In
AMPKa1/ and LysM-a1/ muscle, the number of CX3CR1-
GFPhiLy6C/G (M2) cells was decreased for the benefit of
CX3CR1-GFPloLy6C/G+ (M1) cells, indicating a defect in macro-
phage skewing. Moreover, the kinetics of expression of M1 and
M2markers by isolated CD45+ leukocytes was totally impaired in
AMPKa1/ muscle, meaning that AMPKa1/ macrophages
were not capable of acquiring an M2 phenotype during muscle
regeneration.
Consequently, impairment and delay in muscle regeneration
was observed in LysM-a1/ muscle, whereas a benefit was
observed after WT BM transplantation into AMPKa1/ recipi-
ents. The benefit did not fully correct the delay of regeneration
that was observed in total AMPKa1/mice. Moreover, regener-
ation defects observed in total AMPKa1/ were more pro-
nounced than those in LysM-a1/ muscle. This indicated that
AMPKa1 expressed in other cell types most likely contributes
to muscle regeneration. Although we found no difference in
several myogenic parameters between WT and AMPKa1/
muscle, one cannot exclude a role of AMPKa1, particularly in
the late phases of muscle regeneration, in nonmyeloid cells,
including myofibers. Indeed, AMPKa1 has been involved in the
control of muscle cell and myofiber size (Lantier et al., 2010;
Mounier et al., 2009). Other cell types, including eosinophils
and fibro-adipogenic precursors, have been shown to play
crucial roles for proper muscle regeneration (Joe et al., 2010;
Uezumi et al., 2010; Heredia et al., 2013). Finally, several
signaling pathways have been implicated in the modulation of
LPS-induced M1 macrophages by AMPK, including MAPKs,
PI3K/Akt, and NFkB (Jeong et al., 2009; Peairs et al., 2009;
Sag et al., 2008; Yi et al., 2011; Giri et al., 2004). During skeletal
muscle regeneration, the inhibition of Cebpb function is associ-
ated with increased M1 markers upon LPS stimulation in vitrotion
rescent PKH67-labeled apoptotic MPCs for 6 hr, and labeled with antibodies
(F4/80+PKH67+) among F4/80+ cells. Themiddle panel represents an example
ptosis (Annexin V+) and necrosis (Annexin V+/IP+) in MPC culture.
bars) with apoptotic MPCs, and the expression of M1 and M2 markers was
tor of CaMKKb, and iNOS and CD206 expression was evaluated by immuno-
or presence of STO-609, and iNOS and CD206 expression was evaluated by
the right) muscle 2 and 7 days postinjury was immunolabeled formacrophages
ssociated macrophages expressing p-AMPK, arrowheads indicate interstitial
tedmacrophages negative for p-AMPK. Green arrows show vessels stained for
< 0.01, and ###p < 0.001 versus NT M1 macrophages. $p < 0.05 and $$p < 0.01
sus NT cells. The scale bar represents 50 mm.
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et al., 2009). The restriction of p38 MAPK activation by MAPK
phosphatase-1 was shown to control macrophage phenotypic
transition and muscle recovery (Perdiguero et al., 2011). It is
likely that several signaling pathways act together to operate
the tight regulation of macrophage skewing at the time of resolu-
tion of inflammation.
Themechanisms bywhichmacrophages operate the transition
from theM1 toM2phenotype are poorly characterized. Phagocy-
tosis of tissue debris has been involved, given that anti-inflamma-
tory effectors are increased in phagocyting macrophages,
whereas proinflammatory compounds are downregulated (Fadok
et al., 1998; Freire-de-Lima et al., 2006; Johann et al., 2006). A few
reports investigated the intracellular signaling downstream of
dead cell recognition; i.e., the inhibition of IL12 synthesis is regu-
lated by glucocorticoid (GC)-binding protein (Kim et al., 2004),
whereas the production of IL10 is regulated by Pbx1 and Prep-1
transcription factors activated through the p38 signaling pathway
(Chung et al., 2007). Previously, we showed that macrophages
that have phagocyted apoptotic and necrotic MPCs skew their
phenotype toward an M2 profile (Arnold et al., 2007). More
recently, it has been shown that fibro-adipogenic precursors are
also capable of phagocytosis during skeletal muscle regenera-
tion, emphasizing the roleofphagocytosis in thisprocess (Heredia
et al., 2013). Here, we observed that AMPKa1 deficiency led to a
strong decrease inmacrophage phagocytic activity. Accordingly,
phosphorylatedAMPKwas found tobeassociatedonlywithmac-
rophages operating the phagocytosis of necrotic myofibers in re-
generating muscle (Figure 7). Our results are in line with the
increased phagocytic activity (of E.Coli) of macrophages upon
AICAR treatment (Bae et al., 2011). Moreover, the defect of
phagocytosis of AMPKa1/ macrophages is associated with
their inability to operate the phenotypic transition from M1 to
M2, explaining the alteration of regeneration observed in
AMPKa1/andLysM-a1/muscles, thepersistenceofnecrotic
andphagocyticmyofibers (Figure 1), and the increased number of
neutrophils atday2 inAMPKa1/muscle (Figure5). Interestingly,
apoptotic cell recognition induces both an acute and sustained
calcium flux within phagocytes, and the molecules required for
calcium flux are essential for engulfment (Gronski et al., 2009).
CaMKKa inhibition blocks M2-type macrophage activation and
promotes M1 activation (Guest et al., 2008). Moreover, CaMKKs
are capable of activating AMPK (Hurley et al., 2005; Hawley
et al., 2005; Woods et al., 2005). Here, we showed that the inhibi-
tionofCaMKKbwithSTO-609prevented theacquisition of theM2
phenotype upon both cytokine stimulation and proinflammatory
macrophages phagocyting necrotic and apoptotic MPCs. Addi-
tional studies are required for deciphering to which extent phago-
cytosis causes the activation of the CaMMKb-AMPK axis or
whether CaMMKb-AMPK is required for phagocytosis. Alto-
gether, our results suggest a link between the CaMKKb-AMPK
axis and phagocytosis, phagocytosis being one of the most effi-
cientmechanisms regulating the transitionofmacrophage toward
an M2 phenotype at the time of inflammation resolution.EXPERIMENTAL PROCEDURES
Complete experimental procedures are provided in the Supplemental
Information.262 Cell Metabolism 18, 251–264, August 6, 2013 ª2013 Elsevier IncMice and Mouse Experiments
Adult male animals from AMPKa1/, AMPKa1fl/fl, LysM-CRE+/:AMPKa1fl/fl,
CX3CR1GFP/+; CXRCR1GFP/+:AMPKa1/, and LysM-CRE+/:LKB1fl/fl,
LKB1fl/fl mouse strains were used. Muscle injury was caused by i.m. injection
of CTX in the TA muscle, and BM transplantation was performed as previously
described (Perdiguero et al., 2011). Mouse strains were bred and experi-
mented in compliance with French and European regulations. The animal
facility is fully licensed by French authorities (no. A-75-1402). The principal
investigator had declared the protocols used in this study and is licensed for
these experiments by the local Animal Care and Use Committees of Direction
De´partementale de la Protection des Populations (no. A-75-1506).
Isolation of Leukocytes and Macrophages from Muscle
The muscles were minced and digested with collagenase B 0.2%. CD45+ cells
were isolated bymagnetic sorting (Miltenyi Biotec) and labeled with allophyco-
cyanin-conjugated antibodies against Gr1 (Ly6C/G) or F4/80 (eBioscience).
Cells were analyzed with a flow cytometer (FC-500, Beckman Coulter) or a
FACSCanto II flow cytometer (BDBiosciences) with Diva and FlowJo software.
In some experiments, CD45+ cells were cytospined (Cellspin I, Tharmac) on
Starfrost slides and immunostained (see below). In some experiments, macro-
phage subsets were sorted with a FACSAria III cell sorter (BD Biosciences).
Macrophage Cell Culture
Macrophages were obtained from BM precursor cells. In brief, total BM was
obtained frommice by flushing femur and tibiae BM with Dulbecco’s modified
Eagle’s medium (DMEM). Cells were cultured in a DMEM-containing condi-
tioned medium of L929 cell line (enriched in CSF-1) for 7 days. Macrophages
were activated with cytokines in order to obtain various activation states; i.e.,
IFNg (50 ng/ml), IL4 (10 ng/ml), and IL10 (10 ng/ml) to obtainM1,M2a, andM2c
macrophages, respectively, in DMEM containing 10% fetal bovine serum
(FBS) for 3 days. In some experiments, macrophages were incubated with
1 mM AICAR (Tocris) for 4 hr or with 5 mM STO-609 (Tocris Bioscience) or
DMSO for 3 days in DMEM containing 10% FBS. After the washing steps,
DMEM serum-free medium was added for 24 hr, and cells were recovered
and centrifuged in order to obtain macrophage-conditioned medium. Other-
wise, cells were directly used for various analyses.
MPC Culture
Murine MPCs were obtained from TA muscle and cultured with standard con-
ditions in DMEM/F12 (Gibco) containing 20% FBS and 2% Ultroser G serum
(Pall). For proliferation studies, MPCs were seeded at 10,000 cell/cm2 on
Matrigel (1/10) and incubated for 1 day with MPC-conditioned medium +
2.5% FBS. Then, cells were incubated with anti-ki67 antibodies (15580,
Abcam). For differentiation studies, MPCs were seeded at 30,000 cell/cm2
onMatrigel (1/10) and incubated for 3 days with macrophage-conditionedme-
dium containing 2% horse serum. Then, cells were incubated with antibodies
against desmin (32362, Abcam).
In Vitro Immunolabelings
Macrophages were labeled with primary antibodies against the following pro-
teins: CCL3 (sc-1383, Santa Cruz Biotechnology), COX2 (ab2372, Abcam),
iNOS (ab3523, Abcam), CD206 (sc-58987, Santa Cruz), CD163 (sc-33560,
Santa Cruz), TGFb1 (ab64715, Abcam), and Arginase 1 (sc-18355, Santa
Cruz) and revealed with a cy3-conjugated secondary antibody (Jackson
ImmunoResearch Laboratories).
Phagocytosis Assay
MPCs were labeled with PKH67 (Sigma-Aldrich) and treated with staurosporin
at 5 mM for 4 hr in order to induce apoptosis. Polarized macrophages were
incubated with apoptotic MPCs at a 1:5 ratio for 30 min at 4C or 6 hr at
37C. After five to six PBS washings, cultures were trypsinized, and cells
were labeled with an F4/80-PeCy7 antibody (eBioscience) and analyzed by
flow cytometry (FC-500, Beckman Coulter). The double-positive cells (F4/
80+PKH67+) cells were phagocytic macrophages, whereas the F4/
80+PKH67 cells were nonphagocytic macrophages. To exclude macro-
phages that have bound, but not ingested, apoptotic cells, we subtracted
the percentage of double-positive cells observed at 4C (binding occurred.
Cell Metabolism
AMPKa1 Regulates Macrophage Skewingbut endocytosis did not) from the value observed at 37C. In some experi-
ments, 5 mM STO-609 (or DMSO) was added at the time of phagocytosis.
Statistical Analyses
All experiments were performed with at least three independent primary cul-
tures or at least five animals for in vivo analyses. Isolation of macrophages
from regenerating muscle required three, two, and five mice at 2, 4, and
7 days after injury for each experiment, respectively. Depending on the exper-
iments, a Student’s t test or two-way ANOVA test was performed, and Bonfer-
roni post hoc tests were applied. p < 0.05 was considered significant.
SUPPLEMENTAL INFORMATION
Supplemental Information contains Supplemental Experimental Procedures
and four figures and can be found with this article online at http://dx.doi.org/
10.1016/j.cmet.2013.06.017.
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